Sun Pharma to Acquire Organon for $14 a Share, a 103 Percent Premium ($OGN)

Sun Pharmaceutical Industries on April 26 agreed to acquire Organon for $14.00 a share in an $11.75 billion cash deal, a 103 percent premium.

India’s largest pharmaceutical company has agreed to buy the spinoff that Merck cut loose in 2021. Sun Pharmaceutical Industries Limited (BSE: 524715, NSE: SUNPHARMA) will pay $14.00 per share in cash for Organon & Co. (NYSE: OGN), the women’s health and general-medicines business Merck carved out four years ago. The all-cash transaction values Organon at an enterprise value of $11.75 billion. The price represents a 103 percent premium over Organon’s closing price on the trading day before media reports of the deal first surfaced.

On April 26, 2026, Organon (OGN) entered into an Agreement and Plan of Merger with Sun Pharmaceutical Holdings USA, Inc. and an indirect wholly owned merger subsidiary, with India-based Sun Pharmaceutical Industries Limited joining for the purposes of certain regulatory covenants. The merger sub will merge into Organon, with Organon surviving as a wholly owned subsidiary of the buyer. Organon’s common stock will be delisted from the New York Stock Exchange and deregistered no more than ten days after the deal closes.

The full mechanics are spelled out in Organon’s 8-K filing with the SEC. The merger agreement itself, filed as Exhibit 2.1, runs to over 600 kilobytes of negotiated language.

How the Deal Is Structured

Each Organon share outstanding at the effective time will be converted into the right to receive $14.00 in cash, with no stock component. The deal is therefore a straight cash takeout, not a share exchange in which Organon shareholders would continue to own a piece of the combined entity. Once the merger closes, the only remaining Organon equity instruments will be a small population of cash-converted restricted stock units that vest into cash payments after the deal.

Equity awards get bifurcated treatment. Stock options and restricted stock units granted before 2026 accelerate at closing and convert to cash. Awards granted in 2026 or later become cash-based “Converted RSU Awards” that retain their original vesting schedules but pay out in dollars rather than shares. Performance stock units are measured at target performance and lose their performance conditions, vesting on the original service-based schedule.

The 8-K was filed as soliciting material under Rule 14a-12 of the Exchange Act, the procedural marker that means a proxy statement asking Organon stockholders to approve the merger will follow.

The Number That Matters: 103 Percent Premium

The $14.00 per share price is an exact 103 percent premium over Organon’s closing price on April 9, 2026, the unaffected trading date the company identified as the day before media reports of a potential Sun Pharma transaction surfaced on April 10. That implied unaffected price is approximately $6.90 per share. The premium calculation is disclosed verbatim in the 8-K body text.

Premiums in the 30 to 50 percent range are typical for friendly all-cash takeouts of public US companies. A 103 percent premium signals one of two things, sometimes both. Either the bidder believed the unaffected market price had become detached from intrinsic value, or competition existed in the diligence process and Sun Pharma had to bid past a serious second look.

Carrie Cox, Executive Chair of Organon, framed the board’s view in the joint press release: “Following a comprehensive review of strategic alternatives, our Board determined that this all-cash transaction offers compelling and immediate value to Organon stockholders.” The “comprehensive review of strategic alternatives” language is the standard disclosure formula for a board that ran a process, which the upcoming proxy statement will detail.

The merger agreement also contains a $120 million termination fee that Organon would owe if it walks to accept a Superior Proposal. That break fee is approximately 1.0 percent of the enterprise value, well below the 3 to 4 percent range typical for US public-company deals. The lower fee gives Organon’s board room to entertain a topping bid in the interval between signing and the stockholder vote.

What Sun Pharma Gets

Sun Pharmaceutical Industries is the largest pharmaceutical company in India by revenue and the largest specialty generics manufacturer globally. Innovative medicines in dermatology, ophthalmology, and onco-dermatology already represent roughly 20 percent of Sun’s sales. The Organon acquisition shifts that mix higher and adds two business franchises Sun does not currently own at scale: a global Women’s Health portfolio and a top-10 biosimilars platform.

On a pro forma basis using Sun’s fiscal year 2024-25 numbers and Organon’s calendar 2025 results, the combined company would generate $12.4 billion in revenue, place among the top 25 global pharmaceutical companies, rank as the third-largest player in Women’s Health globally, and become the seventh-largest global biosimilar manufacturer. Sun’s joint press release projects the combined company would have a presence in 150 countries, with 18 markets each generating over $100 million in annual revenue.

Dilip Shanghvi, Executive Chairman of Sun Pharma, described the strategic logic in the press release: “This transaction represents a significant opportunity for Sun Pharma to build on its vision of Reaching People and Touching Lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own, and we believe that bringing the two organizations together can create a stronger and more diversified platform.”

The Debt Picture

Organon was always a leveraged story. Merck spun the company out in 2021 with $9.5 billion in debt sitting on the new balance sheet, financing structured to return cash to Merck at the spinoff. As of fiscal year 2025, Organon reported $6.2 billion in revenue, $1.9 billion in adjusted EBITDA, $8.6 billion in debt, and $574 million in cash on March 31, 2026. Organon also closed a recent product divestiture for $440 million upfront, the net proceeds of which add to the cash balance.

Sun Pharma’s committed financing package includes lines from Citigroup Global Markets Asia Ltd., JPMorgan Chase Bank, N.A., and MUFG Bank, Ltd. The 8-K confirms the deal funding will refinance or repay certain existing Organon debt at closing, leaving open which specific tranches stay outstanding through to the combined entity.

Sun projects post-transaction net leverage of 2.3 times EBITDA on the combined entity, with EBITDA and cash flow set to nearly double on a pro forma basis. The press release identifies deleveraging as an explicit post-close priority, indicating Sun expects to use the combined cash flow to bring the leverage ratio down further.

Regulatory Path and Timing

The transaction needs Hart-Scott-Rodino antitrust clearance in the United States plus several foreign antitrust approvals and foreign direct investment screenings. The merger agreement obligates Sun Pharma’s parent and India Parent (Sun Pharmaceutical Industries Limited) to use reasonable best efforts to obtain those approvals, subject to a Substantial Detriment cap whose contents the parties have not made public.

The outside date is January 26, 2027, with extensions allowed if the only remaining open conditions are regulatory. Both companies expect the transaction to close in early 2027, subject to those approvals plus an Organon stockholder vote at a meeting yet to be scheduled.

Joseph Morrissey, who has served as Organon’s interim Chief Executive Officer since October 2025, was appointed permanent CEO on the same day the merger agreement was signed. Carrie Cox was appointed permanent Executive Chair on the same day. Both appointments were made without compensation changes, consistent with the steady-state-through-closing posture that boards typically adopt for the period between sign and close.

What to Watch

The proxy filing: The next required filing is the preliminary proxy statement on Schedule 14A, which will set the record date and meeting date for the Organon stockholder vote. The background-of-the-merger section will disclose any competing bidders the board considered and the timeline of negotiations with Sun Pharma.

The HSR clock: The 30-day initial Hart-Scott-Rodino review window starts when both parties file their notifications. A second request from the FTC or DOJ would extend the timeline materially and signal antitrust scrutiny of the combined Women’s Health and biosimilars footprint.

Organon’s existing debt: The 8-K confirms Sun Pharma’s financing will fund a refinancing or repayment of “certain” Organon debt, leaving open which tranches stay outstanding through closing. Bond market reaction in the Organon credit complex will reveal whether holders expect a make-whole call, par tender, or roll-through to the combined entity.

Topping bids: The $120 million break fee is approximately 1.0 percent of enterprise value, well below the 3 to 4 percent typical for US public-company deals. That structure is designed to keep the door open for an interloper. Watch the next 30 to 60 days for any 13D filings naming Organon or media reports of a strategic alternatives process.